---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-003055"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:10:10.777490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex CFO to cover CEO during treatment; first patient dosed in Phase 2a expansion of Reqorsa

## Summary
- Catherine Vaczy, EVP and General Counsel, resigned effective Feb 4; company and Vaczy in discussions.
- CEO Rodney Varner undergoing treatment for cutaneous lymphoma; Board designates CFO Ryan Confer to act when CEO unavailable.
- First patient dosed Jan 2024 in Phase 2a expansion of Acclaim-1 study (Reqorsa + Tagrisso for NSCLC).
- Expects to complete Phase 2a enrollment (19 per cohort) by end of 2024; interim analysis in 2025.
- Phase 1 data showed no dose-limiting toxicities and extended progression-free survival in some patients.

## SEC filing metadata
- accession: 0001437749-24-003055
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/gnpx20240204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-003055
- JSON: https://secwatch.observer/filing/0001437749-24-003055.json
- Plain text: https://secwatch.observer/filing/0001437749-24-003055.txt

## Key facts
- Executive change
  Ryan Confer changed role as Chief Financial Officer at Genprex, Inc..
  - Action: designated
  - Role: Chief Financial Officer
  source text: the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm
- Executive change
  Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..
  - Action: resigned
  - Role: Executive Vice President, General Counsel and Chief Strategy Officer
  source text: Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.